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We assessed the contribution of four baseline markers—HLA-DRB1 shared epitope (SE), −3 0 8t u m o rn e c r o s i sf a c t o rα gene
promoter polymorphism, rheumatoid factor, and anticitrullinated peptide antibodies—for predicting persistent activity (DAS28
score ≥2.6) after one year of followup in a cohort of 201 patients with recent-onset rheumatoid arthritis (RA) or undiﬀerentiated
arthritis (UA) aged 16 years or older who had a 4-week to 12-month history of swelling of at least two joints. Patients had not
been previously treated with corticosteroids or disease-modifying antirheumatic drugs (DMARD). In the best logistic regression
model, only two variables were retained: SE positivity and number of DMARD administered (area under the curve = 76.4%; 95%
CI: 69.2%, 84.4%; P<0.001). The best linear regression model also included these two variables, explaining only 22.5% of the
variability of DAS28 score. In this study, given an equal number of DMARD administered, the probability of persistent activity in
patients with recent-onset RA or UA was signiﬁcantly inﬂuenced by SE presence.
1.Introduction
The high variability of disease activity among patients newly
presenting with rheumatoid arthritis (RA) or undiﬀerenti-
atedarthritis(UA)makesitnecessarytoknowwhichpatients
willdeveloppersistentdisease,regardlessofdiagnosis,sothat
they can be treated more aggressively from the outset and
to avoid inappropriate treatment of patients more prone to
remission.
Several methodological issues must be considered when
studying predictors of persistent activity in patients with
recent-onset RA. First, when the disease is in its early stages,
patients seldom fulﬁll the 1987 American Rheumatism
Association (ARA) revised criteria for RA [1]. Patients who
do not fulﬁll criteria for deﬁnite RA at ﬁrst presentation
might be classiﬁed as having deﬁnite RA at a subsequent
time point, but many cases remain unclassiﬁable (UA) [2–
5]. There is an important proportion of newly presenting
patients who do not satisfy these criteria, but for whom
there is a compelling reason to treat with disease-modifying
antirheumaticdrugs(DMARD),orwhoonfollowupdevelop
persistent disease even if there is no change in their
classiﬁcation status. Recently, new classiﬁcation criteria for
RA have been developed in an attempt to increase sensitivity
in recent-onset cases [6]. Whether the fulﬁllment of ARA
criteria is useful to predict activity is unknown [7].
Second, since treatments are not randomly assigned in
nonexperimental studies, disease activity may be inﬂuenced
by the type of treatment patients receive. Patients with more
severe disease are more likely to be treated more aggressively.
This confounding eﬀect can be controlled for by using
multivariate regression models [8].2 ISRN Rheumatology
Third, factors selected by diﬀerent authors as potentially
predictive of a poor outcome are very heterogeneous and
highly variable. The combined role of genetic and immuno-
logic factors in the development of severe RA has been
the subject of recent investigations. Recent data support
the hypothesis that the presence of HLA DRB1 shared
epitope (SE) alleles can trigger immune reactions such as
the production of anticyclic citrullinated peptide antibodies
(anti-CCP) [9]. RA patients showing these antibodies in the
early stages of the disease could develop more severe disease
than those who lack them [10]. RF positivity seems to be
related to active disease, but no deﬁnite conclusions have
been reached regarding its value as a predictor of disease
activity in RA [11]. Tumor necrosis factor alpha (TNFα)
plays a pivotal role in regulating the inﬂammatory response
inRA.However,therearefewreportsontheroleoftheG-to-
A polymorphism at position 308 of the TNFα gene promoter
(–308 TNFα) as an independent marker of disease activity
in recent-onset RA [12, 13]; no association has been seen
in RF-positive patients in particular [14]. Additional cohort
studies including –308 TNFα among the predictor variables
are needed. Although −308 TNFα [12–14], SE alleles, [15–
22]R F ,[ 23–29], and anti-CCP [30–38] have all been studied
aspotentialpredictorsforpersistentactivityincohortstudies
of recent-onset RA, so far no study has investigated the com-
bined eﬀect of this particular set of factors. The combination
of several markers could increase the capacity to predict
persistent disease in patients with recent-onset RA [39]a n d
the identiﬁcation of markers associated with a poor outcome
would facilitate the development of new drug targets [40].
Finally, since there is no consensus deﬁnition of disease
activity in recent-onset RA, the use of diﬀerent deﬁnitions
maygeneratesubstantialvariationamongstudies[41].Asno
“gold standard” exists, a disease activity score based on a
reduced joint count (DAS28), [42] or other disease activity
indexes [43]c a nb eu s e d .AD A S 2 8≥ 2.6 is considered
indicative of active disease, while a DAS28 < 2.6 corresponds
to fulﬁllment of the preliminary ARA criteria for clinical
remission in RA [44].
In this study, multivariate logistic and lineal regression
was used to ﬁnd a model based in immunogenetic markers
that predicts persistent activity in patients with recent-onset
RA or UA. The study is based in a recent-onset inﬂammatory
polyarthritis (IP) register established in Seville, Spain, in
January 2002 to look into various diagnostic, prognostic and
therapeutic issues [45–47].
2.MaterialsandMethods
We studied a prospective cohort of 201 consecutive patients
with recent-onset RA or UA (disease duration ≤1y e a r )
who were referred to our recent-onset IP unit from January
2002 through December 2006. Patients were referred from
primary health care centers, emergency services, and outpa-
tient rheumatology clinics of the Virgen del Roc´ ıo Univer-
sity Hospital Health District in Seville, Spain (population
774619 according to the 2002 census). Details of the case-
ascertainmentandfollow-upprocedurehavebeenpreviously
described [45].
2.1. Subjects. To be included in the recent-onset IP register,
patients referred to the unit had to reside in the hospital
health district catchment area, be at least 16 years old, and
have at least two swollen joints lasting for a minimum of 4
weeks and a maximum of 12 months.
The 1987 ARA criteria for RA [1] and international clas-
siﬁcation criteria for other rheumatic diseases [48] were used
atbaselineandinallfollow-upassessmentsandcumulatively
applied. Patients were classiﬁed as having RA if they fulﬁlled
at least four of the seven 1987 ARA criteria for RA; those
who did not fulﬁll at least four of these seven criteria and
did not fulﬁll the classiﬁcation or diagnostic criteria of any
other particular rheumatic disease were classiﬁed as having
UA. Cases classiﬁed as RA during any visit (at 0, 1, 3, 6,
9, and 12 months) and cases still classiﬁed as having UA
at the end of followup were included in this study; patients
with alternative diagnoses were excluded. Even if the new
ACR/EULAR classiﬁcation criteria for RA have been pub-
lished after our statistical analysis was completed, we have
calculated the proportion of patients who fulﬁll them for
informative purposes [6].
FromJanuary2002throughDecember2006,998patients
were referred to the recent-onset IP unit. Of such patients,
469 (47.0%) fulﬁlled the criteria for inclusion in the register,
but 33 (7.0%) were lost to follow-up. This left a total of
436 registered patients, of whom 201 (46.1%) had completed
the ﬁrst year of followup by the time of this analysis. All
patients were of Spanish descent. At baseline, no patient
had previously received corticosteroids or DMARD. Blood
samples for laboratory tests were collected and frozen before
treatment was begun.
2.2. Genetic Markers. DNA from peripheral blood wasobtai-
ned using standard methods. HLA-DRB1 SE alleles were
genotyped using a reverse dot-blot kit with sequence-
speciﬁc oligonucleotide probes (Dynal Reli SSO HLA-DRB1
typing kits; Dynal Biotech, Bromborough, UK). When nec-
essary, high-resolution typing of HLA-DRB1∗01, DRB1∗04
and DRB1∗14 samples was performed using Dynal AllSet
SSP DRB1∗01, DRB1∗04 and DRB1∗14, respectively. The
frequency of SE in a healthy control group from our
district catchment area was 30% (28% heterozygous and 2%
homozygous for the SE allele).
Samples were genotyped for −308 TNFα using a Taq-
Man 5  allelic discrimination assay (Custom TaqMan SNP
Genotyping Assays method, Applied Biosystems, Foster City,
Calif, USA). Allele-speciﬁc probes were labeled with VIC
and FAM ﬂuorescent dyes. Polymerase chain reaction (PCR)
w a sc a r r i e do u ti nat o t a lr e a c t i o nv o l u m eo f8μL with the
following ampliﬁcation protocol: denaturation at 95◦Cf o r
10min, 40 cycles of denaturation at 93◦Cf o r1 5 s e ca n d
annealing and extension at 60◦C for 1 min. After PCR,
the genotype of each sample was automatically attributed
using the SDS 1.3 software for allelic discrimination. The
frequencies of −308 TNFα genotypes in a healthy control
group from our district catchment area were 80% for GG,
17% for GA and 3% for AA.ISRN Rheumatology 3
2.3. Immunologic Markers. Anti-CCP antibodies were tested
by second-generation ELISA (QUANTA Lite CCP IgG
ELISA. INOVA Diagnostic Inc., San Diego, Calif, USA;
positive: >20IU/mL), and RF by nephelometry on a BN II
instrument (Dade Behring, Marburg, Germany) using the N
Latex RF method (Dade Behring) [46, 47]; levels > 50IU/mL
were considered positive using the optimal cutoﬀ value
reported by other authors [49]. In a healthy control group
fromourdistrictcatchmentarea,theRFlevelatpercentile95
was 15IU/mL, and the highest anti-CCP level was 10UI/mL.
2.4.Treatments.Treatment with corticosteroids and DMARD
(methotrexate,sulphasalazine,chloroquine,leﬂunomide, cy-
closporine, azathioprine, or combinations thereof) during
the entire followup period was assessed.
2.5. Disease Activity Measurements. DAS28 (range 0–10) was
recorded for all patients after 12 months. A DAS28 < 2.6 was
considered indicative of no disease activity or remission, and
aD A S 2 8≥ 2.6 was considered indicative of active disease
[44].
2.6. Statistical Methods. The dependent variable was the
DAS28 obtained at 12 months. The independent variables
were the SE status, anti-CCP and RF (either status or levels),
and −308 TNFα genotype (GG or GA/AA; as there were
few GA and AA cases, these two categories were collapsed)
obtained at baseline. As the probability of persistent activity
maybeinﬂuencedbythetreatmentthepatientsreceived,this
confoundingfactorwasenteredasanadditionalindependent
variable. The treatment given throughout the 12 months
of followup was corticosteroids, categorized dichotomously
(yes/no), and/or DMARD, categorized either dichotomously
(yes/no) or as the number of drugs given (from 0 to 3).
Multinomial regression models were also used to adjust the
possiblediﬀerencesbetweendiseaseclassiﬁcation(RAorUA)
throughout followup.
All data were recorded in an Access 2000 database and
then exported to the Statistical Package for the Social
Sciences (SPSS) v. 15.0 for statistical analysis.
For an alpha level of 0.05, an anticipated “medium”
eﬀect size of 0.15 (according to Cohen’s convention for
multiple regression) and an assumed 10% rate of attrition,
the minimum sample size required to reach a statistical
power of 0.80 in a multiple regression model with eight
predictor variables would be 108.
We calculated absolute frequencies and percentages for
qualitative variables, and means and standard deviations
for quantitative variables. Variables that are predictive for
disease activity at one year were identiﬁed by univariate
and multivariate logistic and linear regression models. For
univariate analyses we used Student’s t-test, χ2 or Fisher’s
exact test, as appropriate. Normality and homoscedasticity
contrasts (Kolmogorov-Smirnov and Levene tests, resp.)
were undertaken for parametric tests. For multivariate
analysis, Wald’s statistic (logistic regression) or Student’s t-
test (linear regression) were used for stepwise exclusion of
variables weakly associated with the dependent variable, as
indicated by a P value ≥ 0.15. Since the SE variable is
polytomic, it was analyzed by creating a dummy variable
with the ﬁrst category (−/−) used as the reference. Full and
reduced models were compared with the G statistic (logistic
regression) or partial multiple F-test (linear regression).
The linearity of continuous variables was checked by the
Box-Tidwell test. Potential interactions among the variables
in the model were studied. Variables with a P value >
0.05 were analyzed as potential confounders, and they were
considered as such whenever their coeﬃcients changed by
>20%. Multicollinearity among independent variables was
assessedbythevarianceinﬂationfactor,independencebythe
Durbin-Watson test, normality by the Shapiro-Wilk test, and
homoscedasticity of the residues by the dispersion diagram
amongresiduesandtheestimatedvalues.Outlierswereiden-
tiﬁed by means of Cook’s distance. In the logistic regression,
goodness of ﬁt was assessed with the Hosmer–Lemeshow
goodness-of-ﬁt analysis, and discrimination was reported as
the area under the receiver operating characteristic (ROC)
curve. In the linear analysis, goodness of ﬁt was assessed with
the corrected determination coeﬃcient (R2). All contrasts
were two-tailed, and the signiﬁcance level was set at <0.05.
3. Results
The characteristics of the study population are shown in
Table 1.T h e−308 TNFα could not be genotyped in 7
patients. Of the remaining 194 patients, 39 (20.1%) had
GA or AA genotypes. Sixty-nine patients (34.3%) were
heterozygous (−/+), and 16 (8.0%) were homozygous (+/+)
for the SE allele; 85 (42.3%) were RF-positive, and 88
(43.8%) were anti-CCP-positive. The number of patients
fulﬁlling ≥4 ARA criteria for RA increased from 108 (53.7%)
at baseline to 142 (70.6%) after 1 year (i.e., 34 of the 93
patients having UA at baseline fulﬁlled ≥ 4 ARA criteria
for RA after 1 year). The number of patients fulﬁlling the
new ACR/EULAR classiﬁcation criteria for RA [6] increased
from 145 (72.1%) at baseline to 154 (76.6%) after 1 year.
Sometime between the baseline visit and the end of the
follow-up period, 190 patients (94.5%) were treated with
DMARD and 185 (92.0%) received corticosteroids. All
patients were treated with corticosteroids and/or DMARD
during the follow-up period. Mean (SD) values for DAS28
were 6.3 (1.4) at study entry and 3.5 (1.3) at 1 year.
In univariate analyses, qualitative variables signiﬁcantly
associated with a DAS28 ≥ 2.6 at one year were positive SE
(P<0.001),fulﬁllmentofthe1987ARAcriteria(P = 0.002),
andtreatmentwithDMARD(P = 0.003).Asforquantitative
variables, only anti-CCP levels (P = 0.030) and the number
of DMARD (P<0.001) were signiﬁcantly associated with a
DAS28 ≥ 2.6 (Table 2).
Table 3 shows the results of univariate and multivariate
logistic regression for DAS28 at one year. In univariate
regression analyses, only positive SE (P<0.001) and the
number of DMARD given during followup (P<0.001)
were associated with a DAS28 ≥ 2.6. Multivariate logistic
regression analysis resulted in a model in which a DAS28 ≥
2.6 at one year of followup was signiﬁcantly predicted by the
presence of SE (OR: 4.72 [95% CI: 2.17, 10.25]; P<0.001)
and the number of DMARD (OR: 2.54 [95% CI: 1.64, 3.95];4 ISRN Rheumatology
Table 1: Characteristics of patients (N = 201).
Variablesa n (%) Mean (SD)
Age (years) — 51.4 (17.2)
Women 144 (71.6) —
Positive anti-CCP 88 (43.8) 68.3 (97.8)
Positive RF 85 (42.3) 137.0 (281.5)
SE
−/− 116 (57.7) —
−/+ 69 (34.3) —
+/+ 16 (8.0) —
−308 TNFαb
GG 155 (79.9) —
GA/AA 39 (20.1) —
CRP (mg/L) — 13.8 (15.7)
ESR (mm/h) — 37.5 (22.0)
Swollen joint count — 12.0 (6.9)
Tender joint count — 14.1 (7.6)
DAS28 — 6.3 (1.4)
HAQ — 1.1 (0.7)
Classiﬁcation criteria
1987 ARA criteria for RA 108 (53.7) —
UA 93 (46.3) —
Number of DMARD
0 11 (5.5) —
1 24 (11.9) —
2 88 (43.8) —
3 78 (38.8) —
DMARD
Methotrexate (MTX) 162 (80.6) —
Leﬂunomide (LEF) 81 (40.3) —
Chloroquine (CLQ) 69 (34.3) —
Sulphasalazine (SLZ) 54 (26.9) —
Cyclosporine (CYC) 16 (8.0) —
Azathioprine 3 (1.5) —
MTX + SLZ + CLQ 74 (36.8) —
MTX + LEF 59 (29.4) —
MTX + SLZ 39 (19.4) —
MTX + CYC 16 (8.0) —
MTX + CLQ 31 (15.4)
Corticosteroids
Yes 185 (92.0) —
No 16 (8.0) —
aAll variables measured at baseline, except treatments, which are accumu-
lated throughout followup.
b−308 TNFα could not be genotyped in 7 patients.
Abbreviations: SD: standard deviation. Anti-CCP: anti-cyclic citrullinated
peptide antibodies. RF: rheumatoid factor. SE: shared epitope. –308 TNFα:
G-to-A polymorphism at position 308 of the TNFα gene promoter. CRP:
C-reactive protein. ESR: erythrocyte sedimentation rate. DAS28: Disease
Activity Score. HAQ: Health Assessment Questionnaire. ARA: American
Rheumatism Association. RA: rheumatoid arthritis. UA: undiﬀerentiated
arthritis. DMARD: disease-modifying antirheumatic drugs.
P<0.001),butnotbyanyothervariable.Thatmeansthatfor
any two patients administered the same number of DMARD,
the probability of persistent activity at 1 year is almost 5
times greater in a patient with SE than in a patient without
S E .F o rac u t o ﬀ value of 0.05, the model had a sensitivity
of 81.9% and a speciﬁcity of 56.1%, with an AUC of 76.4%
(95% CI: 68.9%, 83.8%), that is, signiﬁcantly higher than
50% (P<0.001), indicating that the model showed fair
discriminatory power. The model had also fair accuracy (i.e.,
it correctly predicted 74.6% of the cases).
Table 4 shows the results of univariate and multivariate
linear regression for DAS28 at one year. In univariate
regression analyses, anti-CCP status (P = 0.003), RF status
(P = 0.004),SEheterozygosity(P<0.001),SEhomozygosity
(P = 0.017) and the number of DMARD (P<0.001) were
associated with higher DAS28 at one year. In the linear
regression analysis, a higher DAS28 was signiﬁcantly
predicted by SE heterozygosity (β coeﬃcient: 0.67 [95% CI:
0.32, 1.01]; P<0.001), SE homozygosity (β coeﬃcient: 0.73
[95%CI:0.11,1.35];P = 0.021)andthenumberofDMARD
(β coeﬃcient: 0.63 [95% CI: 0.43, 0.82]; P<0.001), but not
byanyothervariable(partialF tests =0.115;P = 0.995;df =
6.195). That means that for any two patients administered
the same number of DMARD, the DAS28 score at 1 year will
be 0.73 points greater in a patient homozygous for SE than
in a patient without SE. This model explained only 22.5% of
the variability of the dependent variable (R2 = 0.225).
In these models, no signiﬁcant interactions among varia-
bles were noted, and no variable was a confounder. All
criteria for the use of multivariate linear regression were
fulﬁlled: independence, normality and linearity of the inde-
pendent variables, absence of multicollinearity among them,
and homoscedasticity of the residues. No patient showed a
Cook’s distance >1.
4. Discussion
Several cohort studies of populations similar to ours have
investigated the value of diﬀerent combinations of variables,
including HLA-DRB1 SE alleles, −308 TNFα, RF, and anti-
CCP for predicting disease activity among patients with
recent-onset RA [12–37]. These studies diﬀered method-
ologically in terms of referral and recruitment procedures,
inclusion criteria, disease duration, variables assessed at
presentation, followup until assessment of outcome, and
disease activity scoring methods. Our study is the ﬁrst to
investigatethisparticularsetoffourimmunogeneticmarkers
using multivariate regression. Moreover, the potentially
confounding eﬀects of the classiﬁcation criteria (RA versus
UA) and the type of treatment given were controlled for by
including these variables in the regression analyses.
Some studies have found a signiﬁcant association
between SE alleles and disease activity in recent-onset RA
[15, 17, 19] ,a n ds o m eh a v en o t .[ 16, 18, 20–22]S e v e r a l
have not used multivariate statistical methods [15, 17, 21].
Our results show that persistent activity at one year, assessed
with the DAS28, is signiﬁcantly inﬂuenced by the presence
of SE in patients with recent-onset RA or UA. This ﬁnding
is consistent across univariate and multivariate logistic andISRN Rheumatology 5
Table 2: Univariate analyses to identify predictors of a disease activity score (DAS28) ≥ 2.6 at one year.
Variablesa DAS28 < 2.6 N = 57b DAS28 ≥ 2.6 N = 144b P value
Anti-CCP: n (%)
Positive 19 (33.3) 69 (47.9) 0.060
Negative 38 (66.7) 75 (52.1)
Anti-CCP: mean (SD) 46.7 (81.2) 76.9 (102.7) 0.030
RF: n (%)
Positive 22 (38.6) 63 (43.7) 0.167
Negative 35 (61.4)) 81 (56.3)
RF: mean (SD) 127.3 (233.8) 140.8 (298.9) 0.759
SE: n (%)
−/− 46 (80.7) 70 (48.6) < 0.001
−/+ 8 (14.0) 61 (42.4)
+/+ 3 (5.3) 13 (9.0)
−308 TNFα: n (%)
GG 42 (76.4) 113 (81.3) 0.443
GA/AA 13 (23.6) 26 (18.7)
Classiﬁcation criteria
1987 ARA criteria for RA 31 (54.4) 111 (77.1) 0.002
UA 26 (45.6) 33 (22.9)
DMARD: n (%)
Yes 45 (78.9) 136 (94.4) 0.003
No 12 (21.1) 8 (5.6)
Number of DMARD: mean (SD) 1.16 (0.774) 1.74 (0.826) <0.001
Corticosteroids: n (%)
Yes 53 (93.0) 132 (91.7) 0.756
No 4 (7.0) 12 (8.3)
aAll variables measured at baseline, except ARA criteria for RA and treatments.
bExcept for –308 TNFα, where 7 cases (2 with DAS28 < 2.6, and 5 with DAS28 ≥ 2.6) could not be genotyped.
Abbreviations: Anti-CCP: anticyclic citrullinated peptide antibodies. SD: standard deviation. RF: rheumatoid factor. SE: shared epitope. −308 TNFα:G - t o - A
polymorphismatposition308oftheTNFαgenepr omot er .ARA:AmericanRheumatismA ssociation.RA:rheumatoidarthritis.UA:undiﬀerentiatedarthritis.
DMARD: disease-modifying antirheumatic drugs.
Table 3: Univariate and multivariate logistic analyses to identify predictors of a disease activity score (DAS28) ≥ 2.6 (yes/no) at one year.
Variablesa Univariate OR (95% CI) P value Multivariate OR (95% CI)b P valueb
Anti-CCP (neg. versus pos.) 1.84 (0.97, 3.49) 0.062 — —
RF (neg. versus pos.) 1.59 (0.82, 3.06) 0.169 — —
SE (−/−versus −/+ or +/+) 4.42 (2.12, 9.22) < 0.001 4.72 (2.17, 10.25) <0.001
−308 TNFα (GA/AA versus GG) 1.34 (0.63, 2.84) 0.444 — —
Classiﬁcation criteria (UA versus. RA) 1.79 (0.66, 4.82) 0.249 — —
Number of DMARD 2.44 (1.61, 3.70) <0.001 2.54 (1.64, 3.95) <0.001
Corticosteroids (no versus yes) 0.83 (0.26, 1.02) 0.756 — —
DAS28 ≥ 2.6: 71.60% (95% CI: 69.87%, 73.33%).
G-test for full versus. reduced models: G = 2.876; df = 4; P = NS.
G-test for logistic model: G = 38.243; df = 2; P<0.001.
Hosmer-Lemeshow: C = 7.124; df = 6; P = 0.310.
aAll variables measured at baseline, except classiﬁcation criteria and treatments.
bValues not shown for variables not retained in the model, that is, those with P values ≥ 0.15.
Abbreviations: OR: odds ratio. CI: conﬁdence interval. Anti-CCP: anticyclic citrullinated peptide antibodies. RF: rheumatoid factor. SE: shared epitope.
−308 TNFα: G-to-A polymorphism at position 308 of the TNFα gene promoter. UA: undiﬀerentiated arthritis. RA: rheumatoid arthritis. DMARD: disease-
modifying antirheumatic drugs.6 ISRN Rheumatology
Table 4: Univariate and multivariate linear analyses to identify predictors for disease activity score (DAS28) at one year.
Variablesa Univariate β coeﬀ. (95%
CI) P value (Student’s t) Multivariate β coeﬀ. (95%
CI)b P value (Student’s t)b
Anti-CCP (neg. versus
pos.) 0.57 (0.20, 0.93) 0.003 — —
RF (neg. versus pos.) 0.56 (0.18, 0.93) 0.004 — —
SE (−/− versus −/+) 0.74 (0.36, 1.03) <0.001 0.67 (0.32, 1.01) <0.001
SE (−/− versus +/+) 0.83 (0.15, 1.51) 0.017 0.73 (0.11, 1.35) 0.021
–308 TNFα (GA/AA
versus GG) 0.01 (−0.46, 0.86) 0.980 — —
Classiﬁcation criteria (UA
versus RA)
−0.29 (−0.31, 0.89) 0.342 — —
Number of DMARD 0.66 (0.46, 0.86) <0.001 0.63 (0.43, 0.82) <0.001
Corticosteroids (yes
versus. no)
−0.56 (−1.24, 0.15) 0.125 — —
Linear regression equation
DAS28 at 1 year = 2.24 + 0.67 SE(−/+) + 0.73 SE(+/+) + 0.63 number of DMARDs
R2 = 0.225; F = 20.373; P<0.001.
aAll variables measured at baseline, except classiﬁcation criteria and treatments.
b Values not shown for variables not included in the model, that is, those with P values ≥0.15.
Abbreviations: CI: conﬁdence interval. Anti-CCP: anticyclic citrullinated peptide antibodies. RF: rheumatoid factor. SE: shared epitope. −308 TNFα:G -
to-A polymorphism at position 308 of the TNFα gene promoter. UA: undiﬀerentiated arthritis. RA: rheumatoid arthritis. DMARD: disease-modifying
antirheumatic drugs.
linear analyses (Tables 2, 3,a n d4). However, since RA is
a multigenic inﬂammatory disorder, it is likely that other
factors are involved in its outcome. The possibility that the
−308 TNFα may have prognostic implications is currently
being debated. In a seropositive RA inception cohort, no
statistically signiﬁcant diﬀerences were seen in DAS between
patients with GA or AA genotypes and those with the
GG genotype [14]. Other studies that, like ours, were not
conﬁned to seropositive RA patients have also suggested that
the −308 TNFα is not a genetic marker for disease activity in
recent-onset RA [12, 13]. In this study, the GA/AA genotypes
were not retained in any model, either logistic or linear, and
not even in the univariate analyses (Tables 2, 3,a n d4).
Of the 201 patients analyzed, only 42.3% were positive
for RF. This low percentage resembles the values found in
otherstudies.[9,18,28]Besidesthefactthatourpatientshad
recent-onset RA or UA rather than long-term RA, another
possible explanation for the low frequency of RF positivity
may be that, as recommended by some to predict outcome,
[49] we used high cutoﬀ values for RF (>50IU/mL, instead
of >40IU/mL, >20IU/mL, or even >10IU/mL in other
studies). Had we used a cutoﬀ value of ≥40IU/mL, the
frequency of RF positivity would have been 58.7%, instead
of 42.3%. Several studies have reported that RF is a good
predictor of disease activity [23, 24, 26–31]. However, in our
univariate analyses RF, treated either as a qualitative or a
quantitative variable, was not signiﬁcantly associated with
DAS28 (Table 2). Additionally, in the multivariate analyses,
RF was not a prognostic factor for disease activity (Tables 3
and 4). Similar results have been found in other cohorts of
recent-onset RA patients, both in Spain [22] and elsewhere
[21, 25, 30, 32].
In this community-based cohort, only 88 (43.8%) of
the 201 patients with recent-onset RA or UA were positive
for anti-CCP at baseline. A low frequency of positivity at
presentation has been recorded in other recent-onset RA
cohorts [30, 32, 34–36], and it may be indicative of early-
stage disease. The usefulness of anti-CCP for predicting
disease activity in patients with recent-onset RA has been
evaluated in several cohort studies. Some have suggested it is
a marker for active disease, as measured with either the SJC
[30, 33–36, 38] or the DAS28, [21, 30, 36], but others have
not conﬁrmed an association. [22, 31, 32, 37]O n l yaf e w
of these studies have used multivariate statistical methods
[22, 30, 32, 38]. Predictive value may depend on whether
anti-CCP status or titers are considered. In our univariate
analyses, patients who were positive for anti-CCP at presen-
tation had not more disease activity at 1 year than patients
who were negative (Table 2). When quantitative values were
used, anti-CCP antibodies were signiﬁcantly associated with
DAS28 (Table 2). However, this marker was not a predictor
of this outcome in regression models (Tables 3 and 4).
Similar results have been found in other studies in which
multivariate analyses have been performed [22, 32, 38].
The number of patients who fulﬁlled ≥4 ARA criteria for
RA increased with length of followup. Thus, it is advisable
to use a cumulative approach to the classiﬁcation of disease.
Inthe community-based NorfolkArthritis Register(NOAR),
the percentage of patients classiﬁed as having RA using the
above criteria increased from 38% at baseline to 66% at 5
years. [7] In our cohort of 463 patients with recent-onset
IP, 108 (23.3%) fulﬁlled ≥4 ARA criteria for RA when ﬁrst
seen, and 142 (30.7%) at 1 year. The number of patients
fulﬁllingthe new RAclassiﬁcation criteria [6] increased fromISRN Rheumatology 7
145 (72.1%) at baseline to 154 (76.6%) after 1 year. The
1987ARAclassiﬁcationcriteriaforRA,derivedfrompatients
with long-standing established RA, were not designed to
identify patients with recent-onset disease, and the current
management of RA is intended to prevent patients reaching
a stage when they satisfy these criteria. In this cohort, we
included patients fulﬁlling ≥4 of the 7 ARA criteria for RA
and UA patients, since, regardless of diagnosis, DMARD
therapy was used as an indicator of the physician’s opinion
that the patient was at risk of developing persistent disease
in 94.5% of patients. The value of these criteria to predict
active disease in patients with recent-onset disease has been
questioned [7]. In this cohort, the fulﬁllment of ARA criteria
for RA was not predictive for disease activity at 1 year (Tables
3 and 4).
In our study, based on routine care, the treatment
given over the 12 months of followup was included in the
univariate and multivariate analyses and was signiﬁcantly
and negatively related to disease activity in every analysis
(Tables 2, 3,a n d4). Since treatment was not a confounder
in multivariate analyses and DMARD have limited eﬃcacy,
this could indicate that, at least in a subgroup of patients,
persistent disease activity might be related not to insuﬃcient
treatment with DMARD but to a failure to respond to
conventional DMARD. A post hoc analysis of data from the
BeSt study has shown that patients who failed to respond to
methotrexate were unlikely to respond to other conventional
DMARD,[50]andarecentstudyfromthecommunity-based
NOAR has identiﬁed SE positivity as the strongest predictor
of methotrexate monotherapy ineﬃcacy in patients with
earlyinﬂammatorypolyarthtitis[51].TheabilityofDMARD
to prevent radiological damage has also been questioned
[52]. In a previous study we have found that erosive damage
at 1 year in patients with recent-onset RA is signiﬁcantly
inﬂuenced by SE homozygosity and the presence of baseline
erosions, but not by RF status, anti-CCP status, −308 TNFα
genotype or treatment with conventional DMARD [53].
In conclusion, for patients with recent-onset RA or UA
treated with the same number of DMARD, the probability of
persistent activity is signiﬁcantly inﬂuenced by SE presence.
Positive RF and anti-CCP at baseline, as well as the presence
of the AA or GA genotypes of −308 TNFα or the fulﬁllment
of criteria for RA, as opposed to UA classiﬁcation, were not
good predictors of disease activity.
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